Modulation of the proteolytic balance plasminogen activator/plasminogen activator inhibitor by enhanced N-myc oncogene expression or application of genistein

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1736-1740

  Garcia De Veas R ^a   Schweigerer, L ^b   Medina, M A ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b NONE

Author keywords

Genistein; Neuroblastoma; Plasminogen activator inhibitor; Urokinase

Indexed keywords

GENISTEIN; ONCOPROTEIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; ONCOGENE C MYB; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SOLID TUMOR;

CELL DIVISION; ENZYME INHIBITORS; GENE EXPRESSION; GENES, MYC; GENISTEIN; HUMANS; NEOPLASM PROTEINS; NEUROBLASTOMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032189936     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00285-8     Document Type: Article

References (26)

1. 1. Laug WE, Cao XR, T'ang A, et al. Complex expression of the genes encoding for plasminogen activators and their inhibitors in HeLa-smooth muscle cell hybrids. Cell Growth Differentiation 1992, 3, 191-197.
2. 2. Blasi F, Riccio A, Sebatio G. Human plasminogen activators: genes and protein structure. In Blasi F, ed. Human Genes and Diseases. London, Wiley, 1986, 377-414.
3. 3. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991, 88, 1067-1072.
4. 4. Sprang SR. The latent tendencies of PAI-1. Trends Biochem Sci 1992, 17, 49-50.
5. 5. Markus G. The relevance of plasminogen activators to neoplastic growth. A review of recent literature. Enzyme 1988, 40, 159-172.
6. 6. Schneiderman J, Loskutoff DJ. Trends Cardiovasc Med 1991, 3, 99-102.
7. 7. Montesano R. Regulation of angiogenesis in vitro. Eur J Clin Invest 1992, 22, 504-515.
8. 8. Schweigerer L, Christeleit K, Fleischmann G, et al. Identification in human urine of a natural growth inhibitor for cells derived from solid pediatric tumors. Eur J Clin Invest 1992, 22, 260-264.
9. 9. Schwab M. Amplification of the gene Myc N in human neuroblastoma. Crit Rev Oncogenesis 1990, 2, 35-51.
10. 10. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. Augmented myc-N expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990, 50, 4411-4416.
11. 11. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162, 156-159.
12. 12. Urdiales JL, Matés JM, Nuñez de Castro I, Sánchez-Jimenez FM. Chlorpheniramine inhibits the ornithine decarboxylase induction of Ehrlich carcinoma growing in vivo. FEBS Lett 1992, 305, 260-264.
13. 13. Montesano R, Pepper MS, Möhle-Steinlein U, Risau W, Wagner EF, Orci L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990, 62, 435-445.
14. 14. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991, 181, 902-906.
15. 15. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262, 5592-5595.
16. 16. Matsukawa Y, Marui N, Sakai T, et al. Genistein arrests cell cycle progression at G2-M. Cancer Res 1993, 53, 1328-1331.
17. 17. Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 1992, 52, 6200-6208.
18. 18. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graef H. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler 1992, 373, 611-622.
19. 19. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993, 53, 2513-2521.
20. 20. Landau BJ, Kwann HC, Verrusio EN, Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 1994, 54, 1105-1108.
21. 21. Grimaldi G, Di Fiore P, Locatelli EK, Falco J, Blasi F. Modulation of urokinase plasminogen activator during the transition from quiescent to proliferative state in normal mouse cells. EMBO J 1986, 5, 855-861.
22. 22. Hollas W, Soravia E, Mazar A, Henkin J, Blasi F, Boyd D. Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem J 1992, 285, 629-634.
23. 23. Karikó K, Kuo A, Boyd D, Okada SS, Cines DB, Barnathan ES. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 1993, 53, 3109-3117.
24. 24. García de Veas R, Schweigerer L, Medina MA. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in paediatric tumour cells. Effects of tumour cell proliferation modulators on gelatinolytic activity. J Cancer Res Clin Oncol 1995, 121, 275-278.
25. 25. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993, 90, 2690-2694.
26. 26. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.